糖仿制剂作为针对高炎症的E-和P-选择蛋白对抗剂Sialyl Lewis
Mathieu Joyal1, Ryan D Simard2,3, Wael Maharsy1
1Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada.
ACS medicinal chemistry letters
|January 15, 2025
概括
新的糖仿制药阻断了P-和E-选择因子的相互作用,减少了超炎症模型中的免疫细胞招募. 这些化合物具有管理炎症性疾病的潜力,如败血症和严重的COVID-19.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 炎症性疾病 (如败血症,严重的COVID-19) 会导致免疫功能障碍,细胞因子风暴和高死亡率.
- 过度的免疫细胞流入和随后的免疫抑制有助于器官损伤和不良结果.
- 针对白细胞-P-选择因子相互作用提供了一种可控免疫抑制的策略.
研究的目的:
- 发现和描述针对P-和E-selectin的新型免疫调节剂.
- 评估这些化合物的有效性,以减少免疫细胞的招募in vivo超炎症模型.
主要方法:
- 设计和合成sialylLewisx糖仿制剂 (化合物12和13) 与一个四醇碳酸生物.
- 对P-和E-选择素的结合和PSGL-1相互作用的阻断的评估.
- 在超炎症模型中的体内评估,以量化免疫细胞群.
主要成果:
- 化合物12和13有效地结合P-和E-选择素,抑制PSGL-1相互作用.
- 在体内给药显著降低了免疫细胞的招募,包括中性粒细胞,CD11b+,单细胞/巨细胞和PSGL-1+细胞.
- 在多个时间点证明了关键炎症细胞标记物的减少.
结论:
- 利易斯糖仿制剂 (12和13) 是选择性中介白细胞粘附的强有力的抑制剂.
- 这些化合物显示出作为治疗治疗系统性炎症反应综合征和相关超炎症状况的治疗线索的前景.
相关概念视频
Selectins
3.2K
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.2K
Cell-surface Signaling
51.4K
Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.
51.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114


